The HSBC Holdings plc Reaffirms “Buy” Rating for GlaxoSmithKline plc (GSK)

The HSBC Holdings plc Reaffirms “Buy” Rating for GlaxoSmithKline plc (GSK)

Several other analysts have also recently issued reports on the company. Morgan Stanley reiterated an equal weight rating and issued a GBX 1,700 ($21.84) price objective on shares of GlaxoSmithKline plc in a research note on Monday, February 6th. BNP Paribas reiterated an underperform rating and issued a GBX 1,520 ($19.52) price objective on shares of GlaxoSmithKline plc in a research note on Wednesday, March 22nd. Berenberg Bank set a GBX 1,890 ($24.28) price objective on GlaxoSmithKline plc and gave the company a neutral rating in a research note on Monday, March 20th. Societe Generale reiterated a sell rating and issued a GBX 1,300 ($16.70) price objective on shares of GlaxoSmithKline plc in a research note on Thursday, March 23rd. Finally, Deutsche Bank AG set a GBX 1,720 ($22.09) price objective on GlaxoSmithKline plc and gave the company a neutral rating in a research note on Tuesday, April 18th. Three research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the company’s stock. The company currently has an average rating of Hold and an average target price of GBX 1,751.77 ($22.50).

HSBC Holdings plc reissued their buy rating on shares of GlaxoSmithKline plc (LON:GSK) in a research note released on Wednesday morning. HSBC Holdings plc currently has a GBX 1,970 ($25.31) price objective on the stock.

The business also recently declared a dividend, which will be paid on Thursday, July 13th. Investors of record on Thursday, May 11th will be issued a dividend of GBX 19 ($0.24) per share. This represents a dividend yield of 1.21%. The ex-dividend date is Thursday, May 11th. In related news, insider Vivienne Cox purchased 335 shares of the stock in a transaction that occurred on Wednesday, April 26th. The shares were purchased at an average price of GBX 1,583 ($20.33) per share, with a total value of £5,303.05 ($6,811.88). Also, insider Moncef Slaoui purchased 56 shares of the stock in a transaction that occurred on Tuesday, March 7th. The shares were bought at an average cost of GBX 2,072 ($26.62) per share, for a total transaction of £1,160.32 ($1,490.46). In the last three months, insiders have purchased 718 shares of company stock worth $1,183,024.

About GlaxoSmithKline plc GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “LSE:GSK”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for GlaxoSmithKline plc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for GlaxoSmithKline plc and related companies with MarketBeat.com’s FREE daily email newsletter.

Related posts

Leave a Comment